TY - JOUR
T1 - Clinicopathologic features of diencephalic neuronal and glioneuronal tumors
AU - Ho, Cheng Ying
AU - Bornhorst, Miriam
AU - Almira-Suarez, M. Isabel
AU - Donev, Kliment
AU - Grafe, Marjorie
AU - Gordish-Dressman, Heather
AU - Rodriguez, Fausto J
N1 - Funding Information:
Send correspondence to: Cheng-Ying Ho, MD, PhD, Department of Pathol-ogy and Neurology, University of Maryland School of Medicine, 22 S Greene Street, Baltimore, MD 21201; E-mail: cho@som.umaryland.edu This work was supported by National Institute of Health K08 NS102468 (C-YH), Passano Foundation (C-YH), and Pilocytic/Pilomyxoid Fund, in-cluding Lauren’s First and Goal, and the Stick it to Brain Tumors Annual Women’s Ice Hockey Tournament (FJR).
Publisher Copyright:
© 2019 American Association of Neuropathologists, Inc.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Neuronal/mixed glioneuronal tumors are central nervous system neoplasms composed of neoplastic neuronal cell components or a mixture of glial and neuronal elements. They occur in cerebral hemispheres, posterior fossa, and spinal cord. Compared with other tumors at these locations, diencephalic neuronal/glioneuronal tumors are very rare and therefore not well characterized. We hereby performed clinicopathologic evaluation on 10 neuronal/glioneuronal tumors arising from the diencephalic region. Morphologically, these tumors resemble their histologic counterparts in other locations, except that lymphocytic infiltrates and microcalcifications are more common than Rosenthal fibers or eosinophilic granular bodies. The BRAFV600 mutation rate is 75%. Given the high percentage of samples being small biopsy specimens, the subtle histologic features and molecular findings greatly aided in establishing the pathologic diagnosis in several cases. At a median follow-up of 42 months, 71% of the tumors demonstrated radiological recurrence or progression, with median progression-free survival of 18 months. Recurrence/progression is observed in tumors across different histologic subtypes, necessitating additional therapies in 56% of the cases. Despite their bland histology, diencephalic neuronal/glioneuronal tumors are not clinically indolent. Their frequent recurrences warrant a close follow-up, and the prevalent BRAF mutation makes MAPK pathway inhibition a plausible treatment option when conventional therapies fail.
AB - Neuronal/mixed glioneuronal tumors are central nervous system neoplasms composed of neoplastic neuronal cell components or a mixture of glial and neuronal elements. They occur in cerebral hemispheres, posterior fossa, and spinal cord. Compared with other tumors at these locations, diencephalic neuronal/glioneuronal tumors are very rare and therefore not well characterized. We hereby performed clinicopathologic evaluation on 10 neuronal/glioneuronal tumors arising from the diencephalic region. Morphologically, these tumors resemble their histologic counterparts in other locations, except that lymphocytic infiltrates and microcalcifications are more common than Rosenthal fibers or eosinophilic granular bodies. The BRAFV600 mutation rate is 75%. Given the high percentage of samples being small biopsy specimens, the subtle histologic features and molecular findings greatly aided in establishing the pathologic diagnosis in several cases. At a median follow-up of 42 months, 71% of the tumors demonstrated radiological recurrence or progression, with median progression-free survival of 18 months. Recurrence/progression is observed in tumors across different histologic subtypes, necessitating additional therapies in 56% of the cases. Despite their bland histology, diencephalic neuronal/glioneuronal tumors are not clinically indolent. Their frequent recurrences warrant a close follow-up, and the prevalent BRAF mutation makes MAPK pathway inhibition a plausible treatment option when conventional therapies fail.
KW - BRAF V600E
KW - Diencephalic
KW - Gangliocytoma
KW - Ganglioglioma
KW - Ganglion cell tumor
KW - Glioneuronal tumor
KW - Rosette-forming glioneuronal tumor
UR - http://www.scopus.com/inward/record.url?scp=85076583707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076583707&partnerID=8YFLogxK
U2 - 10.1093/jnen/nlz115
DO - 10.1093/jnen/nlz115
M3 - Article
C2 - 31793986
AN - SCOPUS:85076583707
SN - 0022-3069
VL - 79
SP - 67
EP - 73
JO - Journal of neuropathology and experimental neurology
JF - Journal of neuropathology and experimental neurology
IS - 1
ER -